For example, acquired BRAF inhibitor resistance in melanoma that results from the downstream activation of MEK (MAPK/ERK Kinase) effector proteins has been mitigated through combinatorial approaches targeting both BRAF and MEK [144,145]. This evidence concerns the gene BRAF and melanoma.